Emerging protein kinase inhibitors for the treatment of multiple myeloma.

Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 2019 Jul 22;: Authors: Lind J, Czernilofsky F, Vallet S, Podar K Abstract Introduction: Significant advances have been made during the last two decades in terms of new therapeutic options but also of innovative approaches to diagnosis and management of multiple myeloma (MM). Indeed, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have fundamentally changed the landscape of MM treatment. However, while patient survival has been significantly prolonged, most patients relapse. Including the milestone approval of the first kinase inhibitor imatinib mesylate for chronic myeloid leukemia in 2001, 48 small molecule protein kinase (PK) inhibitors have entered clinical practice until now. However, no protein kinase inhibitor has been approved for MM therapy yet. Areas covered: This review article summarizes up-to-date knowledge on the pathophysiologic role of protein kinases in MM. Among derived kinase inhibitors evolving as potential novel therapeutic agents in MM, small molecules targeting receptor tyrosine kinases (RTKs), the Ras/Raf/MEK/MAPK- pathway, the PI3K/Akt/mTOR- pathway as well as Bruton tyrosine kinase (BTK), Aurora kinases (AURK), and cyclin- dependent kinases (CDK) are most promising. Preclinical as well as early clinical data focusing on these molecules will be presented and critically reviewed. Expert op...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research